- Home
- DOCN vs CELC Comparison
DOCN vs CELC Comparison
Compare DOCN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOCN
- CELC
- Stock Information
- Founded
- DOCN 2011
- CELC 2011
- Country
- DOCN United States
- CELC United States
- Employees
- DOCN N/A
- CELC N/A
- Industry
- DOCN Retail: Computer Software & Peripheral Equipment
- CELC Medical Specialities
- Sector
- DOCN Technology
- CELC Health Care
- Exchange
- DOCN Nasdaq
- CELC Nasdaq
- Market Cap
- DOCN 3.0B
- CELC 2.8B
- IPO Year
- DOCN 2021
- CELC 2017
- Fundamental
- Price
- DOCN $39.41
- CELC $74.39
- Analyst Decision
- DOCN Buy
- CELC Strong Buy
- Analyst Count
- DOCN 13
- CELC 5
- Target Price
- DOCN $43.08
- CELC $69.40
- AVG Volume (30 Days)
- DOCN 2.9M
- CELC 1.6M
- Earning Date
- DOCN 11-05-2025
- CELC 11-13-2025
- Dividend Yield
- DOCN N/A
- CELC N/A
- EPS Growth
- DOCN 87.43
- CELC N/A
- EPS
- DOCN 1.32
- CELC N/A
- Revenue
- DOCN $832,812,000.00
- CELC N/A
- Revenue This Year
- DOCN $16.34
- CELC N/A
- Revenue Next Year
- DOCN $14.63
- CELC N/A
- P/E Ratio
- DOCN $30.20
- CELC N/A
- Revenue Growth
- DOCN 13.29
- CELC N/A
- 52 Week Low
- DOCN $25.45
- CELC $7.58
- 52 Week High
- DOCN $47.02
- CELC $83.00
- Technical
- Relative Strength Index (RSI)
- DOCN 52.93
- CELC 70.27
- Support Level
- DOCN $38.25
- CELC $64.61
- Resistance Level
- DOCN $41.14
- CELC $80.13
- Average True Range (ATR)
- DOCN 2.17
- CELC 4.84
- MACD
- DOCN -0.36
- CELC 2.12
- Stochastic Oscillator
- DOCN 29.79
- CELC 77.25
About DOCN DigitalOcean Holdings Inc.
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups, and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. Geographically, the company generates maximum revenue from North America and also has a presence in Europe, Asia, and the Rest of the world.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.